Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virus cocktail targets superbug pneumonia in first human test

NCT ID NCT07492771

Disease control Sponsor: MicrobiotiX Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This early-stage trial tests MP101, a mix of two viruses that attack bacteria (phages), in 18 adults with Pseudomonas aeruginosa pneumonia. Participants receive a single dose of MP101 or a placebo alongside standard antibiotics. The main goal is to check safety and how the body handles the treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MP101 (a cocktail of two bacteriophages)
What this could lead to
If successful, this could point toward a new treatment option for hard-to-treat Pseudomonas pneumonia, especially when antibiotics fail.
What could go wrong
This is a very early, small phase 1 trial with only 18 participants. The main goal is safety, not effectiveness, and it may not work or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged 19 years or older. * Clinical diagnosis of acute pneumonia with radiologic evidence of pulmonary infiltrates. * Confirmed Pseudomonas aeruginosa (PA) infection via valid respiratory specimens. * PA isolate demonstrates susceptibility to MP101 and non-susceptibility to current antibiotic therapy. * Adequate organ function as defined by hematological, hepatic, and renal laboratory parameters . Exclusion Criteria: * Persistent septic shock or hemodynamically unstable condition. * Active pulmonary tuberculosis or non-bacterial pneumonia. * Significant pleural effusion or lung abscess requiring therapeutic drainage. * Clinically significant cardiovascular, hepatic, or renal impairment . * Immunocompromised status or hematological malignancies. * Known hypersensitivity to bacteriophages, study components, or concomitant antibiotics. * Participation in another clinical trial within 30 days prior to screening. * Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pseudomonas aeruginosa pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial pneumonia pneumonia caused by pseudomonas aeruginosa infection Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia - bacterial Pseudomonas aeruginosa infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Severance Hospital

    RECRUITING

    Seoul, Seodaemun-gu, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.